BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors - PubMed (original) (raw)
Review
. 2008 Dec;9(12):1336-46.
Affiliations
- PMID: 19037840
Review
BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors
Natalie Minkovsky et al. Curr Opin Investig Drugs. 2008 Dec.
Abstract
The anilino-quinazoline derivative BIBW-2992, which is being developed by Boehringer Ingelheim Corp for the potential treatment of solid tumors, is an oral dual receptor tyrosine kinase inhibitor of human EGF receptor (EGFR) and human epidermal growth factor receptor-2 (HER-2)/neu. EGFR and HER-2/neu activate numerous signaling pathways leading to cancer cell proliferation, survival and migration. In vitro, BIBW-2992 effectively and selectively inhibited EGFR and HER-2/neu and inhibited EGFR and HER-2/neu total tyrosine phosphorylation and tumor cell proliferation in vivo. Importantly, BIBW-2992 was active against tumors overexpressing EGFR with the secondary Thr790Met point mutation, which confers resistance to the first-generation EGFR inhibitors gefitinib and erlotinib. In phase I/II trials, BIBW-2992 was effective in patients with solid tumors, including those with NSCLC tumors activating mutations in the EGFR tyrosine kinase domain. BIBW-2992 was generally well tolerated with the main adverse effects being gastrointestinal or cutaneous disorders. At the time of publication, BIBW-2992 was undergoing phase II trials for NSCLC, breast and prostate cancers, head and neck carcinoma, as well as glioma. BIBW-2992 was granted Fast-Track status by the FDA for NSCLC and was investigated in phase III trials for this indication.
Similar articles
- Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Yap TA, et al. J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679611 Clinical Trial. - Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M. Schütze C, et al. Strahlenther Onkol. 2007 May;183(5):256-64. doi: 10.1007/s00066-007-1696-z. Strahlenther Onkol. 2007. PMID: 17497097 - Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS. Cha MY, et al. Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24. Int J Cancer. 2012. PMID: 21732342 - Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Riely GJ. Riely GJ. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9. doi: 10.1097/JTO.0b013e318174e96e. J Thorac Oncol. 2008. PMID: 18520300 Review. - Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J. Von Pawel J. Bull Cancer. 2004 May 1;91(5):E70-6. Bull Cancer. 2004. PMID: 15582898 Review.
Cited by
- Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W, Zhang K, Wang W, Liu Y, Huang J, Zheng M, Li L, Zhang X, Xu M, Chen G, Wang L, Zhang S. Li W, et al. J Exp Clin Cancer Res. 2024 Feb 26;43(1):56. doi: 10.1186/s13046-024-02981-5. J Exp Clin Cancer Res. 2024. PMID: 38403634 Free PMC article. - Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches.
Fuchs N, Zhang L, Calvo-Barreiro L, Kuncewicz K, Gabr M. Fuchs N, et al. J Pers Med. 2024 Jan 4;14(1):68. doi: 10.3390/jpm14010068. J Pers Med. 2024. PMID: 38248769 Free PMC article. Review. - Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.
Marret G, Temam S, Kamal M, Even C, Delord JP, Hoffmann C, Dolivet G, Malard O, Fayette J, Capitain O, Vergez S, Geoffrois L, Rolland F, Zrounba P, Laccourreye L, Saada-Bouzid E, Aide N, Bénavent V, Klijianenko J, Lamy C, Girard E, Vacher S, Masliah-Planchon J, de Koning L, Puard V, Borcoman E, Jimenez M, Bièche I, Gal J, Le Tourneau C. Marret G, et al. Sci Rep. 2023 Dec 18;13(1):22524. doi: 10.1038/s41598-023-49887-4. Sci Rep. 2023. PMID: 38110561 Free PMC article. Clinical Trial. - Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.
Chang Y, Funk M, Roy S, Stephenson E, Choi S, Kojouharov HV, Chen B, Pan Z. Chang Y, et al. Int J Mol Sci. 2022 Feb 3;23(3):1763. doi: 10.3390/ijms23031763. Int J Mol Sci. 2022. PMID: 35163685 Free PMC article. - Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G, Catalano M, Iannone LF, Marano L, Brugia M, Rossi G, Aprile G, Antonuzzo L. Roviello G, et al. Clin Transl Oncol. 2022 Jun;24(6):981-996. doi: 10.1007/s12094-021-02760-0. Epub 2022 Jan 29. Clin Transl Oncol. 2022. PMID: 35091998 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous